Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methotrexate for hand osteoarthritis.

The Cochrane database of systematic reviews·2026
Same author

Disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta-analysis.

The Cochrane database of systematic reviews·2026
Same author

DDAH1 and DDAH2 drive vasculogenic mimicry and more aggressive phenotypes in triple negative breast cancer cells.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Targeting hemozoin detoxification in Plasmodium falciparum: could a chlorophyll derivative act as a tetrapyrrole mimic to disrupt hemozoin formation in infected erythrocytes?

MedScience·2026
Same author

The prognostic role of inhalation injury in burn patients assessed by flexible bronchoscopy: a systematic review and meta-analysis.

Frontiers in medicine·2026
Same author

Perioperative use of disease-modifying anti-rheumatic drugs (DMARDs) in people with inflammatory arthritis.

The Cochrane database of systematic reviews·2026

Related Experiment Video

Updated: Jan 30, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.2K

Methotrexate for psoriatic arthritis.

Tom D Wilsdon1, Samuel L Whittle, Tilenka Rj Thynne

  • 1Department of Rheumatology, Royal Adelaide Hospital and University of Adelaide, Port Rd, Adelaide, South Australia, Australia, 5000.

The Cochrane Database of Systematic Reviews
|January 19, 2019
PubMed
Summary

Low-dose methotrexate may improve symptoms of psoriatic arthritis compared to placebo over six months, but evidence on harms and long-term effects is limited. Further research is needed to fully understand its benefits and risks.

More Related Videos

In Vivo Optical Imaging of Brain Tumors and Arthritis Using Fluorescent SapC-DOPS Nanovesicles
09:04

In Vivo Optical Imaging of Brain Tumors and Arthritis Using Fluorescent SapC-DOPS Nanovesicles

Published on: May 2, 2014

11.8K
Author Spotlight: Isolation and Culture of Primary Synovial Macrophages and Fibroblasts from Murine Arthritis Tissue
09:18

Author Spotlight: Isolation and Culture of Primary Synovial Macrophages and Fibroblasts from Murine Arthritis Tissue

Published on: February 24, 2023

10.3K

Related Experiment Videos

Last Updated: Jan 30, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.2K
In Vivo Optical Imaging of Brain Tumors and Arthritis Using Fluorescent SapC-DOPS Nanovesicles
09:04

In Vivo Optical Imaging of Brain Tumors and Arthritis Using Fluorescent SapC-DOPS Nanovesicles

Published on: May 2, 2014

11.8K
Author Spotlight: Isolation and Culture of Primary Synovial Macrophages and Fibroblasts from Murine Arthritis Tissue
09:18

Author Spotlight: Isolation and Culture of Primary Synovial Macrophages and Fibroblasts from Murine Arthritis Tissue

Published on: February 24, 2023

10.3K

Area of Science:

  • Rheumatology
  • Clinical Pharmacology
  • Evidence Synthesis

Background:

  • Psoriatic arthritis (PsA) is a chronic inflammatory condition causing joint damage and reduced quality of life.
  • Methotrexate (MTX), a disease-modifying anti-rheumatic drug (DMARD), is frequently used to manage PsA symptoms and disease progression.

Purpose of the Study:

  • To evaluate the efficacy and safety of methotrexate in adult patients with psoriatic arthritis.
  • To synthesize evidence from randomized controlled trials comparing methotrexate with placebo or other DMARDs.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs) and quasi-RCTs.
  • Searched multiple databases (CENTRAL, MEDLINE, Embase, etc.) up to January 29, 2018.
  • Assessed outcomes including disease response (PsARC), function (HAQ), disease activity (DAS28-ESR), and adverse events.

Main Results:

  • Low-quality evidence from one RCT suggests methotrexate (≤15 mg/week) improves disease response (RR 1.76, 95% CI 1.14 to 2.70) and function (HAQ 0.3 points better) compared to placebo over six months.
  • Methotrexate showed a non-significant trend towards reduced serious adverse events (RR 0.26, 95% CI 0.03 to 2.26) and similar rates of withdrawal due to adverse events compared to placebo.
  • Evidence regarding health-related quality of life and radiographic progression was not reported or was unavailable.

Conclusions:

  • Low-dose oral methotrexate may offer modest benefits for psoriatic arthritis symptom control over six months, based on limited, low-quality evidence.
  • Uncertainty remains regarding the safety profile and long-term efficacy of methotrexate for psoriatic arthritis.
  • Further high-quality randomized controlled trials are needed to investigate methotrexate's effects on quality of life, radiographic progression, and higher doses.